Emerging pharmacotherapy trends in preventing and managing oral mucositis induced by chemoradiotherapy and targeted agents

Margherita Gobbo,Jamie Joy,Helena Guedes,Muhamed Alì Shazib,Carryn Anderson,Ragda Abdalla-Aslan,Khunthong Peechatanan,Carlo Lajolo,Khawaja Shehryar Nasir,Luiz Alcino Gueiros,Nivethitha Nagarajan,Kimia Hafezi Motlagh,Abhishek Kandwal,Cosimo Rupe,Yuanming Xu,Eli D. Ehrenpreis,Arghavan Tonkaboni,Joel B. Epstein,Paolo Bossi,Hannah R. Wardill,Stephanie L. Graff
DOI: https://doi.org/10.1080/14656566.2024.2354451
2024-05-31
Expert Opinion on Pharmacotherapy
Abstract:Introduction The introduction of targeted therapy and immunotherapy has tremendously changed the clinical outcomes and prognosis of cancer patients. Despite innovative pharmacological therapies and improved radiotherapy (RT) techniques, patients continue to suffer from side effects, of which oral mucositis (OM) is still the most impactful, especially for quality of life.
pharmacology & pharmacy
What problem does this paper attempt to address?